PAD

R3 Vascular Reports the Initiation of Its First-In-Human Clinical Study

Retrieved on: 
Thursday, September 2, 2021
Health, Medical Devices, Clinical Trials, Research, Science, Cardiology, Biotechnology, Patient, Trial of the century, Head, Knee, Professor, CLI, Time, Medical school, BRS, Ischemia, PAD, Program, BTK, Technology, Â, 3D printing, Medical imaging

R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.

Key Points: 
  • R3 Vascular Inc. today reported the successful initiation of its First-in-Human clinical study evaluating the technical and clinical performance of the R3 Vascular MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS) in patients suffering of Critical Limb Ischemia (CLI) due to occlusive below the knee (BTK) arterial disease.
  • The R3 Vascular platform incorporates an innovative scaffold design and bioresorbable polymer technology resulting in biomechanical performance comparable to metallic stents.
  • At a 98-micron strut thickness across all its usable range of diameters, the MAGNITUDE BRS device is the thinnest BRS ever tested in this clinical setting.
  • Given the dire and unmet clinical need of patients presenting with CLI undergoing BTK revascularization, we are extremely pleased by the rapid progression of our program, said R3 Vascular CEO Kamal Ramzipoor .

Modern Vascular Raising Awareness of Peripheral Artery Disease and Preventing Amputations for PAD Awareness Month

Retrieved on: 
Wednesday, September 1, 2021
Diabetes, Life expectancy, Peripheral artery disease, Black, Pain, Press release, Smoking, Amputation, American Association of Clinical Endocrinologists, Weakness, Physician, Native, Leg, CO, Awareness, National, Wound healing, Foot, Hypoesthesia, Patient, NIH, Cramp, Obesity, PAD, Pharmaceutical industry

PHOENIX, Sept. 1, 2021 /PRNewswire/ -- Modern Vascular, a pioneering medical group dedicated to preventing amputation through the outpatient treatment of Peripheral Artery Disease (PAD), is marking September PAD Awareness Month at its 16 nationwide clinics by offering screening and treatment for PAD.

Key Points: 
  • PHOENIX, Sept. 1, 2021 /PRNewswire/ -- Modern Vascular, a pioneering medical group dedicated to preventing amputation through the outpatient treatment of Peripheral Artery Disease (PAD), is marking September PAD Awareness Month at its 16 nationwide clinics by offering screening and treatment for PAD.
  • "At Modern Vascular, we want to make the suffering of unnecessary lower leg amputations a thing of the past so people can focus on living their normal lives."
  • Modern Vascular specializes in the treatment of peripheral artery disease (PAD) through below-the-knee, below-the-ankle, and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.

Healogics® Raises Awareness of Peripheral Artery Disease (PAD) to Help Reduce Amputations

Retrieved on: 
Wednesday, September 1, 2021
People, Cramp, Peripheral artery disease, Amputation, Diagnosis, Weakness, Leg, Health, Awareness, Wound healing, Multimedia, Hypoesthesia, Extremities, Risk, 2nd Connecticut Heavy Artillery Regiment, Patient, American Heart Association, Common, PAD, Medicine

JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ -- Healogics, the nation's leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September.

Key Points: 
  • JACKSONVILLE, Fla., Sept. 1, 2021 /PRNewswire/ -- Healogics, the nation's leading provider of world-class wound care services, is raising awareness of Peripheral Artery Disease (PAD) throughout September.
  • Through this campaign, Healogics is supporting the American Heart Association's goal to reduce amputations by 20% by 2030 through increased PAD Awareness, diagnosis and treatment.
  • PAD affects nearly 10 million Americans and is a contributing factor in up to 30% of non-healing wounds on the lower leg.
  • As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country.

Imageware Biointellic Achieves Level 2 ISO Anti-Spoofing Compliance

Retrieved on: 
Tuesday, August 31, 2021
Cloud, Company, Face, Certification, Mask, OTCQB, Biometrics, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Silicon, Method, Product management, Law enforcement, Private Securities Litigation Reform Act, Risk, Senior, NIST, Government, Patient, Compliance, Solution, SAN, Annual report, Level 1, Portrait, Security (finance), PAD, Security printing, Printed circuit board

Biointellic is a revolutionary zero-friction, anti-spoofing system designed to prevent intruders from breaching authentication systems.

Key Points: 
  • Biointellic is a revolutionary zero-friction, anti-spoofing system designed to prevent intruders from breaching authentication systems.
  • The intelligent presentation cyberattack detection solution is used in several Imageware offerings, including Imageware Authenticate, Imageware Proof, and the Imageware Identity Platform, as it provides passive PAD for face images using standard mobile phone cameras.
  • The rigorous Level 1 and 2 compliance testing conducted by iBeta included several advanced spoofing methods, including high-resolution pictures and videos, curved pictures with cut-out eyes, silicon masks, and mannequins.
  • Imageware is one of just a handful of vendors that have achieved Level 1 and Level 2 PAD certification with a passive solution.

Humacyte Highlights Robust Expanded Access Program and Patient Testimonial for Human Acellular Vessels

Retrieved on: 
Thursday, August 19, 2021
Constellation, Vibration, Proxy, Intention, SEC, Food, Authorization, Hospital, Review, Securities Act of 1933, Risk, Medicine, Fast track (FDA), Crush injury, U.S. Securities and Exchange Commission, EDT, Moyamoya disease, AHAC, Special, Time, Forward-looking statement, Investment, Prospectus, PIPE, Sale, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, Form, Dialysis, Tissue, Nasdaq, Person, Perfusion, EAP, Failure, HAV, FDA, Security (finance), PAD, Business architecture, Company, Terminology, Webcast, Special access program, MPA, Acquisition, Amputation, GLOBE, Leg, Injury, Form S-4, Patient, COVID-19, Pharmaceutical industry

The patient received the HAV to restore blood flow to her crushed limb and avoid amputation.

Key Points: 
  • The patient received the HAV to restore blood flow to her crushed limb and avoid amputation.
  • On August 24, 2021, AHAC will hold a special shareholders meeting to vote on the proposed business combination with Humacyte.
  • Human Acellular Vessels (HAV) are engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
  • Humacytes initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease.

Ra Medical Systems Reports 2021 Second Quarter Financial Results

Retrieved on: 
Monday, August 16, 2021
Diabetes, Health, Cardiology, Medical Devices, Income, Time, EBITDA, Forward-looking statement, Table, U.S. Securities and Exchange Commission, Laser, Atherectomy, Research, NYSE, News, Disclosure, Catheter, Degenerative disease, Private Securities Litigation Reform Act, Adjustment, Lipid, GAAP, SEC, FDA, Marketing, Annual report, Security (finance), Patient, PAD, Growth, Technology, Regulation, Sale, Dermatology, Physician, Vascular disease, Depreciation, Regulation Fair Disclosure, Protein, Coronary artery disease, Industry, Investor relations, Review, Fracture, Pharmaceutical industry, Video game, Lithium, Fossil fuel, Real estate

Net revenue from the vascular segment was de minimis for the second quarter of 2021 and was $0.1 million for the second quarter of 2020.

Key Points: 
  • Net revenue from the vascular segment was de minimis for the second quarter of 2021 and was $0.1 million for the second quarter of 2020.
  • Net revenue from the dermatology segment was $1.0 million for the second quarter of 2021 and $0.8 million for the second quarter of 2020.
  • Total cost of revenue for the second quarter of 2021 was $1.5 million, compared with $1.2 million for the second quarter of 2020.
  • Adjusted EBITDA for the second quarter of 2021 was negative $6.1 million, compared with negative $8.4 million for the second quarter of 2020.

Ra Medical Systems Announces Sale of Pharos Dermatology Business

Retrieved on: 
Monday, August 16, 2021
Diabetes, Health, Cardiology, Medical Devices, Forward-looking statement, Trial of the century, Atopic dermatitis, U.S. Securities and Exchange Commission, Vitiligo, Laser, Disclosure, Atherectomy, News, NYSE, Achievement, Catheter, Psoriasis, Degenerative disease, Private Securities Litigation Reform Act, Lipid, SEC, Research, FDA, Marketing, Annual report, Security (finance), Patient, PAD, Regulation, Strata Skin Sciences, Sale, Dermatology, Physician, Vascular disease, Regulation Fair Disclosure, Protein, Industry, Review, Pharmaceutical industry

(NYSE American: RMED), a medical device company focused on commercializing its excimer laser system to treat vascular disease, announces the sale of its Pharos dermatology business to STRATA Skin Sciences (Nasdaq: SSKN) for $3.7 million in cash.

Key Points: 
  • (NYSE American: RMED), a medical device company focused on commercializing its excimer laser system to treat vascular disease, announces the sale of its Pharos dermatology business to STRATA Skin Sciences (Nasdaq: SSKN) for $3.7 million in cash.
  • We believe this transaction is in the best interest of Ra Medical and our shareholders as we intend to maximize value with a strategy that continues to focus on the large and growing PAD market, said Will McGuire, Ra Medical Systems CEO.
  • Ra Medical Systems commercializes the DABRA excimer laser and catheters for the treatment of vascular diseases.
  • The forward-looking statements in this press release are based on information available to Ra Medical as of the date hereof, and Ra Medical disclaims any obligation to update any forward-looking statements, except as required by law.

Worldwide Peripheral Vascular Devices Industry to 2026 - Improvement of Healthcare Facilities in Developing Countries is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 10, 2021
Medical Devices, Health, Moyamoya disease, Statistics, Incidence, Patient, Cardiac arrest, Head, Degenerative disease, Chronic venous insufficiency, National Institute, PAOD, Smoking, EVAR, Blood, OECD, Foundation for the National Institutes of Health, Coagulation, International Trade Organization, CVI, Artery, Lists of countries and territories, Smokeless tobacco, PAD, Plague, IVC, Prevalence, Peripheral artery disease, Infection, PVD, Pharmaceutical industry

It is also known as peripheral artery occlusive disease (PAOD) or peripheral artery disease (PAD) or peripheral obliterative arteriopathy.

Key Points: 
  • It is also known as peripheral artery occlusive disease (PAOD) or peripheral artery disease (PAD) or peripheral obliterative arteriopathy.
  • It comprises diseases pertaining to both peripheral veins and peripheral arteries, affecting the peripheral and cardiac circulation in the body.
  • Peripheral vascular devices like IVC channels, angiography catheters, EVAR stent-joins, hemodynamic stream change, and plague adjustment devices are utilized for treating peripheral blood vessel or coronary blood vessel infection and utilized in the peripheral endovascular and coronary methodology.
  • However, stringent regulations related to the import and export of peripheral vascular devices are expected to act as a restraint to this market growth.

Modern Vascular Brings Innovative Treatments to Prevent Unnecessary Limb Loss to Kansas City

Retrieved on: 
Thursday, August 5, 2021
Statistics, Wound healing, Menorah Medical Center, COVID-19, University, PAD, Amputation, Diabetes, Amputee Coalition of America, DPM, Awareness, Life expectancy, Health, Patient, CDC, Smoking, Quality of life, Pain, CO, Leg, Open House, Risk, Saint Louis University, Artery, Peripheral artery disease, Death, Obesity, Pharmaceutical industry, Hospital

Dr. Correa, a long-time presence in the Kansas City medical community as a vascular surgeon, completed his general and surgical fellowship training at Saint Louis University.

Key Points: 
  • Dr. Correa, a long-time presence in the Kansas City medical community as a vascular surgeon, completed his general and surgical fellowship training at Saint Louis University.
  • Modern Vascular clinics specialize in the treatment of peripheral artery disease (PAD) through below-the-knee and below-the-ankle and pedal endovascular arterial reconstruction.
  • Modern Vascular procedures are also an important step in avoiding future limb amputation and extending life expectancy in diabetic, cardiovascular, and peripheral artery disease patients.
  • Modern Vascular now operates and manages sixteen clinics across AZ, CO, IN, KS, MO, MS, NM, TX, VA. For more information, visit www.ModernVascular.com .

Modern Vascular and Local Vascular Surgeon Pair Up to Reduce Unnecessary Amputations in St. Louis, Missouri

Retrieved on: 
Wednesday, August 4, 2021
Vascular surgery

Board certified in vascular surgery, Dr. Pratt specializes in Vascular and Endovascular Surgery.

Key Points: 
  • Board certified in vascular surgery, Dr. Pratt specializes in Vascular and Endovascular Surgery.
  • "Modern Vascular offers patients and their families patient-centered treatment options for leg and foot pain, ulcers, and wounds.
  • Dr. Pratt puts an emphasis on long-term patient care, stating, "Like Primary Care Physicians, we see our Modern Vascular patients long term.
  • Modern Vascular now operates and manages sixteen clinics across AZ, CO, IN, KS, MO, MS, NM, TX, VA. For more information, visit www.ModernVascular.com .